New treatment option for young women with hormone‐sensitive breast cancer.
The Aromatase Inhibitor (AI) Question
This landmark study is the first to demonstrate that taking exemestane along with blocking ovarian function prevents cancer recurrence in young women with hormone‐sensitive breast cancer, a common type of breast cancer. These practice‐changing results provide a new treatment option for young women with hormone‐sensitive breast cancer, previously only recommended for postmenopausal women. This IBCSG study is the culmination of a successful, decade‐long worldwide collaboration spanning 27 countries and 6 continents.
Please contact email@example.com for media inquiries.
ASCO 2014 Plenary Presentation
Dr. Olivia Pagani presented on behalf of IBCSG at the June 1 plenary session.
New England Journal of Medicine
We are pleased to publish our results in the July 10 print issue of The New England Journal of Medicine.
- Click here to access the paper. Full content is available by paid subscription.
ASCO 2014 Related Abstracts
We also presented the following related TEXT and SOFT abstracts:
- TEXT and SOFT Quality of Life (QL)
- SOFT Estrogen Substudy (SOFT‐EST)
Women who participated in the TEXT and SOFT clinical trials should contact their treating physician for additional information.